Top Markets
Coin of the day
RayzeBio, Inc. Common Stock RayzeBio, Inc. Common Stock

RayzeBio, Inc. Common Stock

RYZB
Ранг среди акций #5675
RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs)... RayzeBio, Inc. is dedicated to creating radiopharmaceutical therapies (RPTs) for oncology applications. Its primary therapeutic candidate, RYZ101, is currently advancing through Phase 3 clinical trials for the management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The company's innovative pipeline also features RYZ801, a distinct peptide engineered to deliver Actinium-225 (Ac225) by targeting GPC3, intended for treating hepatocellular carcinoma (HCC). Additionally, RayzeBio is developing RYZ811, a companion diagnostic imaging agent comprising a peptide binder, a chelator, and Gallium-68 (Ga68). Another active development program involves a novel proprietary small molecule designed to target CA9, delivering Ac225 for potential use against clear cell renal cell carcinoma (ccRCC). The firm was established in 2020 and is headquartered in San Diego, California.
Цена акции
$62.49
Последняя синхронизация: 2024-03-06
Рыночная капитализация
$2.52B
Изменение (1 день)
0.00%
Изменение (1 год)
0.00%
Страна
US
Торговля RayzeBio, Inc. Common Stock (RYZB)

Категория

Коэффициент P/S для RayzeBio, Inc. Common Stock (RYZB)
Коэффициент P/S на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций RayzeBio, Inc. Common Stock, текущий коэффициент P/S (TTM) составляет 0. В конце 2026 он составлял 0.
История P/S для RayzeBio, Inc. Common Stock с 2026 по 2026
Коэффициент P/S в конце каждого года
Год P/S Изменить
Недостаточно данных для указанных дат.
Коэффициент P/S для аналогичных компаний или конкурентов
Компания P/S Разница P/S Страна
10.17 -
US
10.13 -
NL
11.28 -
US
2.95 -
AU
- -
CH